II. Indications
-
Acute Myelogenous Leukemia (AML)
- Gemtuzumab ozogamacin
III. Mechanism
- CD33
- CD33 is a small Protein on the surface of myeloid cells and Monocyte-Macrophage precursors
- CD33 interacts with SHP-1 and SHP-2 Protein kinases for intracellular signaling
- CD33 Monoclonal Antibody
- Conjugate antibodies that deliver cytotoxic drugs to CD33 positive cancer cells
IV. Medications
- Gemtuzumab ozogamacin (Mylotarg)
- Conjugated Monoclonal Antibody that delivers the cytotoxic drug calicheamicin to cancer cells
- Used in Acute Myelogenous Leukemia (AML)
V. Dosing
- See other references for disease specific dosing protocols
VI. Adverse Effects
- Hepatotoxicity (FDA black box warning)
- Includes hepatic veno-occlusive disease (sinusoidal obstruction)
- Increased transaminases, GGT, and Serum Bilirubin
- Infusion Reactions (including Anaphylaxis)
- Severe Hemorrhage
- Other common adverse effects
- Gastrointestinal (Nausea, Vomiting, Constipation, decreased appetite)
- Headache
- Rash
- Mucositis
VII. Safety
- Avoid in Lactation
- Avoid in pregnancy (all trimesters, Unknown Pregnancy category)
- Use reliable Contraception
- Monitoring
VIII. Resources
- Gemtuzumab ozogamacin (DailyMed)